Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of transarterial tirapazamine embolization plus KN046 in advanced MSS/pMMR colorectal cancer with liver metastases
CTR20230034Phase 2Active
- Sponsor
- N/A/ 杭州泰泊医药有限公司
- Start
- Apr 2023
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tirapazamine, erfonrilimab in colorectal cancer (CRC), sponsored by N/A/ 杭州泰泊医药有限公司. Started Apr 2023; status: active.
02
Drugs
tirapazamineerfonrilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20230034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230034.